Get the Stockscreener App
0.1567
2.34%
-0.0014
Bioatla Inc stock is traded at $0.1567, with a volume of 150.84K.
It is down -2.34% in the last 24 hours and down -34.96% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.1581
Open:
$0.1543
24h Volume:
150.84K
Relative Volume:
0.07
Market Cap:
$12.97M
Revenue:
$11.00M
Net Income/Loss:
$-64.71M
P/E Ratio:
-0.1363
EPS:
-1.1496
Net Cash Flow:
$-57.52M
1W Performance:
-1.22%
1M Performance:
-34.96%
6M Performance:
-76.92%
1Y Performance:
-58.78%
1-Day Range:
$0.1536
$0.1599
1-Week Range:
$0.148
$0.178
52-Week Range:
$0.13
$1.43
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.1566 | 13.10M | 11.00M | -64.71M | -57.52M | -1.1496 |
VRTX
Vertex Pharmaceuticals Inc
|
451.39 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
754.55 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
329.82 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
687.64 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.26 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
Buyout Rumor: Can BioAtla Inc deliver consistent dividends2026 Decliners & Risk Managed Investment Signals - baoquankhu1.vn
BioAtla, Inc. 8-K SEC Filing March 17, 2026: Company Information, Key Details, and Legal Disclosures - Minichart
BioAtla Shareholders Approve Merger and Share Consolidation - TipRanks
BioAtla (NASDAQ: BCAB) approves merger, 1-for-50 reverse split and 2026 executive retention bonuses - Stock Titan
842,440 shares issued to YA II PN, Ltd.; BioAtla (NASDAQ: BCAB) registers resale - Stock Titan
BCAB Stock Price, Quote & Chart | BIOATLA INC (NASDAQ:BCAB) - ChartMill
Breakout Watch: What is the dividend yield of BioAtla IncEarnings Growth Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
BCAB Technical Analysis | Trend, Signals & Chart Patterns | BIOATLA INC (NASDAQ:BCAB) - ChartMill
BioAtla (NASDAQ: BCAB) to issue 631,163 shares to Yorkville under SEPA - Stock Titan
BioAtla (NASDAQ: BCAB) CMO receives 240,000-share time-based RSU award - Stock Titan
BioAtla (NASDAQ: BCAB) CEO receives 430,000-share RSU grant - Stock Titan
BioAtla (BCAB) CFO awarded 240,000 restricted stock units, total holdings 530,196 shares - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Published on: 2026-03-07 14:29:43 - Naître et grandir
BioAtla launches major restructuring and leadership transition - The Globe and Mail
BioAtla explores sale as it cuts 70% of workforce - Investing.com South Africa
BioAtla (BCAB) CFO sees 1,802 shares withheld for RSU tax settlement - Stock Titan
[Form 4] BioAtla, Inc. Insider Trading Activity - Stock Titan
BioAtla (BCAB) CMO reports 3,140-share tax withholding on RSU vesting - Stock Titan
BioAtla explores sale as it cuts 70% of workforce By Investing.com - Investing.com India
BioAtla, Inc. Initiates Strategic Review Process and Workforce Restructuring to Enhance Shareholder Value - Quiver Quantitative
BioAtla Inc announces 70% workforce reductionSEC filing - marketscreener.com
BioAtla appoints Chris Vasquez as CFO as Richard Waldron departs - TradingView
BioAtla (NASDAQ: BCAB) slashes workforce 70% amid strategic review, listing risk - Stock Titan
BioAtla, Inc. Implements Workforce Reduction of Approximately 70% - marketscreener.com
Bioatla announces formal process to evaluate strategic options to monetize assets - marketscreener.com
Bioatla Announces Formal Process To Evaluate Strategic Options To Monetize Assets - TradingView
Biotech BioAtla to shed 70% of staff while weighing asset sales - Stock Titan
Bioatla, Inc. Announces CFO Changes. Effective March 2, 2026 - marketscreener.com
BCAB PE Ratio & Valuation, Is BCAB Overvalued - Intellectia AI
US Market Wrap: Does BioAtla Inc meet Warren Buffetts criteria2025 Retail Activity & Low Drawdown Momentum Ideas - baoquankhu1.vn
Aug Sentiment: Is BioAtla Inc forming bullish engulfing patterns2025 Geopolitical Influence & Long-Term Safe Return Strategies - baoquankhu1.vn
BioAtla, Inc. (NASDAQ:BCAB) Sees Large Drop in Short Interest - Defense World
BioAtla (BCAB) CEO has shares withheld to cover RSU taxes - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
BioAtla to Participate in the Citizens Life Sciences Conference - 富途牛牛
Gap Down: Will BioAtla Inc stock hit new highs in YEAR2025 Bull vs Bear & Accurate Intraday Trading Signals - baoquankhu1.vn
BCABBioatla, Inc. Latest Stock News & Market Updates - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Aug Chart Watch: Will Nixxy Inc Equity Warrant outperform its industry peers2025 Trading Volume Trends & Accurate Buy Signal Alerts - baoquankhu1.vn
Why BioAtla Inc. stock is popular among millennials2025 Pullback Review & Entry and Exit Point Strategies - mfd.ru
What analysts say about BioAtla Inc. stockJuly 2025 Review & Growth Focused Stock Reports - mfd.ru
BCAB Should I Buy - Intellectia AI
BioAtla Sets March Virtual Vote on Internal Merger Plan - The Globe and Mail
Why BioAtla Inc. stock could see breakout soonSell Signal & Community Consensus Picks - mfd.ru
BioAtla (BCAB) seeks approval for 1‑for‑50 share conversion to support Nasdaq listing - Stock Titan
Bioatla Faces Nasdaq Delisting Review Amid Corporate Restructuring - AD HOC NEWS
Is BioAtla Inc. currently under institutional pressureQuarterly Risk Review & Technical Analysis for Trade Confirmation - mfd.ru
BioAtla Faces Nasdaq Review of Continued Listing Status - The Globe and Mail
BioAtla to remain on Nasdaq during listing council review process By Investing.com - Investing.com Canada
BioAtla to remain on Nasdaq during listing council review process - Investing.com Nigeria
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):